Aaron E. Carroll's Blog, page 21

Prison health care is only available if you can afford it

Often, people who are incarcerated are required to pay a co-pay for medical care that they initiate. While the cost of this co-pay may appear low, it can have high human costs, especially if it means that individuals ultimately delay seeking care. In a recent piece for Prism Reports, I talk about prison co-pays and the impact that they can have on people who are incarcerated, particularly for women and people of color:

These risks become even higher for marginalized people in carceral facilities, who tend to be Black, Latinx, and other people of color, often in poorer health than the general population, and part of a rapidly aging population that needs more specialized care. For many advocates, the removal of medical copays in prison is about more than affected individuals—it’s also about moving toward equity and justice within the carceral system.

Read the full piece, here!

Research for this piece was supported by Arnold Ventures.

The post Prison health care is only available if you can afford it first appeared on The Incidental Economist.

President Biden’s Executive Order isn’t enough to end Conversion Therapy

Content Warning: Sensitive topics are discussed throughout this article, including suicide.

This summer, President Biden signed an executive order to prohibit federally-funded programs from offering conversion therapy, an ineffective and unethical practice to change an individual’s sexual orientation and/or gender identity. While an important political statement, it’s likely not enough to end the practice altogether. Forward progress will only happen with legal and regulatory changes at both the national and local levels.

Originating in 1973, conversion therapy became an umbrella term to describe any psychological, physical or spiritual intervention aimed at converting lesbian, gay, bisexual, transgender, queer/questioning, and other identities (LGBTQ+) to traditional heterosexual and cisgender norms. Practices range from talk therapy and prayer to physical violence and exorcisms.

In the decades since its inception, conversion therapy has impacted nearly 700,000 individuals in the United States (US), with 350,000 of them subjected as minors. While estimates range considerably, tens or even hundreds of thousands of LGBTQ+ youth are currently at risk of receiving conversion therapy by religious leaders or licensed professionals.

It is well-documented that conversion therapy is ineffective, but mounting evidence indicates there are also mental health and economic implications.

Among 28 published studies including almost 200,000 LGBTQ+ individuals, 12% underwent conversion therapy as minors and experienced higher rates of depression and substance use than peers who were not exposed.

Similarly, a 2022 survey by The Trevor Project reported that, out of the thousands of LGBTQ+ youth that were threatened with or subjected to conversion therapy, more than half attempted suicide in the past year, compared to 11% of youth with no intervention.

Additional negative effects were found in a study of members of the Mormon Church exposed to conversion therapy, including worsened self-esteem, anxiety, increased distance from God, and a sense of wasted time and money.

On the economic front, a new study estimated that conversion therapy costs nearly $100,000 per person over their lifetime. Alternatively, LGBTQ+ affirmative therapy would result in a $40,000 saving per person over their lifetime.

Given conversion therapy’s harms, many reputable health associations have formally denounced the practice. This even led Exodus International, the largest host of conversion programs worldwide, to disavow conversion therapy in a public apology prior to shutting down.

Despite the evidence, 51% of LGBTQ+ Americans live in states with no bans or only partial bans on conversion therapy. With the practice remaining fully legal in 21 states, President Biden’s executive order will not solve this public health issue alone.

A federal ban on conversion therapy through legislation would be the ideal solution but it would be difficult to achieve. Bills have been introduced in Congress four times since 2015, perpetually stalling in subcommittee. Bipartisan support is challenging due to religious influence and advocacy from parental freedom fighters.

However, recent polls indicate there is growing opposition to conversion therapy from conservative-led states, with 71% of Floridians and 80% of North Carolinians supporting bans against the practice. Internationally, over 370 religious leaders from 35 countries have called for a global ban.

To build momentum for state, and ultimately federal, legislation, it may be vital to strategize on the local level. When Ohio and Utah originally failed to pass statewide legislation, licensing regulations were developed to prevent health professionals from offering conversion therapy. To date, 80 local ordinances also ban the practice in select counties and cities nationwide, including several in Kansas, Kentucky, and Alaska, historically conservative-led states.

While the United Nations has equated conversion therapy with torture, only 14 countries have created a national ban on the practice. The United States is not among them, but evidence and ethics suggests it should be.

Resources:

The Trevor Project Hotline: 1-866-488-7386Conversion Therapy Survivors Support Group: ctsurvivors.orgThe post President Biden’s Executive Order isn’t enough to end Conversion Therapy first appeared on The Incidental Economist.

How We Process Meat, Memories, and Nutrition Research

A recent news story covered a study about processed foods and how eating those foods relates to cognitive decline. The only problem is, they didn’t report on an actual published study. They reported on a conference abstract and presentation. 

 



The post How We Process Meat, Memories, and Nutrition Research first appeared on The Incidental Economist.

Alcohol: why won’t we just give it up?

Alcohol is the “golden child” of sinful indulgences. Cigarettes give you cancer; soda rots your teeth. But enjoy that martini! Despite how destructive alcohol can be, drinking – not abstaining – is the socially acceptable choice. Why do we see alcohol as worth the risk?

It’s not because of a lack of data. The data are clear: drinking can be really harmful. For example, in 2021, a record number of Minnesotans died from excessive drinking. Over 1,100, in fact, more than homicides and suicides combined. The state’s alcohol mortality rate has doubled since 2014. What’s more, these numbers don’t even include deaths indirectly tied to alcohol consumption, like drunk driving.

At a national level, from 2015 to 2019, over 33,600 Americans died from causes fully attributable to alcohol, like alcohol dependence. Over 140,500 died from alcohol-related causes, such as various cancers.

Despite these numbers, it used to be common to hear that a glass of red wine was good for your health. Media and science both said so, throwing around buzzwords like the Mediterranean diet, antioxidants, and heart health.

But research shows that’s just not true. At best, any potential health benefit from red wine is minor and you can get the same boost from a good diet. At worst, alcohol is really bad for you.

Alcohol use can lead to injuries and violence. It impairs your cognitive abilities, increasing the risk of car crashes, other accidents, and interpersonal conflicts. It also has significant consequences on your physical body, negatively impacting your heart and liver and increasing the risk of many cancers. More superficially, it’s heavy on calories and light on nutrition.

And yet, drinking is widely accepted, even glorified. Champagne is synonymous with celebration and beer with Sunday football. Unless you abstain for religious reasons or are in recovery, not drinking is the faux pas.

Why won’t we stop drinking, given all we know?

First, alcohol is cultural, and not just in America. People have readily consumed alcohol throughout all of history. It was actually medicinal in early times and sometimes considered safer to drink than water. Nowadays, Italians love their wine, other parts of Europe love their beer, and the Japanese celebrate sake.

Peer pressure – and a desire for social acceptance – is also a compelling force. One survey in the United Kingdom found that 85 percent of participants had been pressured to drink by their friends, with younger folks feeling it most intensely. Another study suggested that this pressure “isn’t [always] malicious and may not even be conscious.” It’s as if it’s simply embedded into our social framework.

But perhaps most importantly, for many, drinking is just fun. People associate alcohol with friends and laughter, and even good old-fashioned rowdiness. In a stressful world, we’re all looking to let off some steam. While using alcohol to cope isn’t healthy, it’s understandable that many appreciate the mood-boosting properties of a couple beers with friends.

All that said, we’d be healthier if we drank less. How to accomplish that though is the trick. Some argue for increasing taxes on alcohol, shown in the past to reduce consumption. Liquor licenses are on the ballot in a few states this November; addressing where we can buy alcohol and what kinds is another approach.

Shifting the social environment could be even more effective. The mocktail scene is taking off and might be here to stay. For health and even environmental reasons, more consumers are looking for nonalcoholic options, but ones that aren’t Grandma’s sparkling cider. With delicious – and fancy – zero-proof drinks available, we might all be won over without even realizing it.

I still enjoy a good gin and tonic and you might like your IPAs. But it might be time we face the music and really think about why we drink at all.

The post Alcohol: why won’t we just give it up? first appeared on The Incidental Economist.

Who is innovation in the US health care system actually for?

Innovation is considered one of the American health care system’s strengths. In theory, innovation makes health care better and less expensive because it leads to new treatments and lower costs. But because innovation and new therapies exist in the context of disparities in coverage and access to care, these benefits are not felt equally across the population; innovation itself has the potential to exacerbate and deepen existing disparities.

Innovation, particularly in drug manufacturing, has become a significant priority for the private industry. In 2019, the pharmaceutical industry spent $83 billion on the research and development of new drugs. Between 2010 and 2019, 60 percent more new drugs were approved for sale than in the previous decade. And in the federal government, both sides of the political aisle rally around innovation. Members of Congress have introduced several pieces of bipartisan legislation to “accelerate promising strategies to improve the health care system and ensure patients have access to cutting edge innovation.”

However, innovation in the context of American exceptionalism means that its benefits only flow to those already privileged by the system; like all other parts of the health care system, innovation is only accessible to those who can afford it.

In the US, people are at the mercy of their insurers or public programs (if they have coverage). Consequently, the regulatory approval of a new innovative product doesn’t guarantee its access.

Research has shown that there is significant variation in commercial health plan’s coverage decisions for specialty drugs, which have been touted as some of the greatest achievements in health care innovation (in recent years, more than half of the novel drugs approved by the Food and Drug Administration [FDA] have been specialty drugs). Not all plans cover these drugs equally — some plans don’t cover these medications at all, while others have more restrictive coverage.

Moreover, like all things in the US health care system, access to innovation is severely restricted for certain groups of people. Coverage for innovative therapies is even more limited for people in public insurance programs.

In the Medicare program, innovative treatment for people with end stage renal disease (ESRD) — a disease that disproportionately affects people of color — is a great example. In August 2021, the FDA approved a new drug called Korsuva to treat ESRD-related severe chronic itching. But Korsuva falls outside Medicare’s existing bundled payment for ESRD-related care.

There is a special mechanism to guarantee access to it for two years, but, after that, Medicare can choose not to cover it. It’s likely that Medicare will not choose to permanently add Korsuva to its ESRD bundled payment because there already are covered anti-itching medications (which are ineffective against ESRD-related severe chronic itching). With an annual cost of $17,000, it’s unlikely that individual dialysis centers will purchase and provide the therapy on their own, leaving patients with no good options.

People with Medicaid coverage also face more restricted access to innovative therapies that are ostensibly designed to help them specifically. Coverage (or lack thereof) for innovative treatment for people with hepatitis C virus (HCV) — which disproportionately affects Black people and people in prison — clearly underscores this problem.

People with Medicaid coverage face significantly higher rates of HCV. There are incredibly effective treatments available to treat people with HCV, but the costs of these treatments are prohibitively high (some manufacturers have priced standard treatment courses at $84,000). While some states have worked to ensure access to HCV treatment for people with Medicaid, access is severely restricted, because people have to meet onerous prior authorization requirements (in most states) and strict criteria in order to gain coverage. This has led to an increased risk of mortality among people with HCV who have Medicaid coverage, compared to those with private insurance.

And for people without insurance, access to innovation is oftentimes out of reach. Some drug manufacturers have programs that make some of their products accessible to those without insurance, but new medications are (at least initially) priced in ways that severely limit access.

When life-altering therapies are available, but largely out of reach for certain groups of people, it’s worth considering who innovation actually serves. For everyone to reap the benefits of innovation, it’s critical to consider who our health care system is designed to work for (and who it isn’t). Until then, innovation will improve the health and lives of some, while being largely out of reach to others.

Research for this piece was supported by Arnold Ventures.

The post Who is innovation in the US health care system actually for? first appeared on The Incidental Economist.

Why Isn’t there a Birth Control Pill for Males?

Condoms and vasectomies remain pretty much the extent of birth control options for people who produce sperm, and both have problems. So why is almost all hormonal birth control aimed at those with ovaries? There have been some successes targeting the biological feedback process for hormones that regulate new sperm production, but progress is slow.

 



The post Why Isn’t there a Birth Control Pill for Males? first appeared on The Incidental Economist.

Without supports for direct home care workers, older adults are at risk of unwanted nursing home admissions

The need for direct home care workers — health professionals who work with individuals in their homes — is growing, and demand outpaces supply. In the US, states can use American Rescue Plan funds to expand their direct care workforce, but this funding expires in 2025. Without a sustainable plan to recruit and retain direct care workers, aging Baby Boomers are at risk of unwanted nursing home admissions.

Direct care workers include personal care aides, home health aides, and certified nursing assistants (CNAs). All provide assistance with activities of daily living — tasks like feeding or bathing oneself. Home health aides and CNAs perform additional tasks, including monitoring vital signs, transferring individuals from a bed to a chair, and wound dressing. Depending on the state, they may assist with medication administration. All of these activities facilitate independent living in one’s home or community, the settings where the majority of older adults prefer to receive long-term care. Demand for the services of direct care workers continues to grow.

Despite their critical role in independent living, direct care workers generally receive low salaries and are undervalued by society. In 2021, the median pay for a home health aide or personal care aide was $14.15/hour ($29,430/year). It was only slightly higher for nursing assistants. Salaries meeting the federal minimum wage were not guaranteed until 2015. Low salaries, along with limited opportunities for career advancement and the potential for on-the-job injuries contribute to high rates of turnover. Forty to sixty percent of direct care workers leave their jobs annually. The work is important, but difficult and inadequately compensated.

In recognition of these issues, the 2021 American Rescue Plan provided states with Medicaid funding to “enhance, expand, or strengthen” their home and community-based care services, including those provided by direct care workers. Funding for direct care workers is intended to support recruitment and retention of staff and can be used to increase worker compensation. States have flexibility in how they use the funds — example strategies include investments in loan repayment, tuition assistance, hiring bonuses, career ladder development, and enhanced training. The ability to use these funds was recently extend to 2025, but there are no long-term plans to sustain improvements in infrastructure and wages.

To meet the growing demand for the services of direct care workers, long-term funding is needed to identify and sustain effective strategies targeting their recruitment and retention. Economic models suggest that increasing compensation of direct care workers to state-specific living wages would improve both recruitment and retention. Participants in loan repayment programs targeted to health care professions report high satisfaction with the programs, but data limitations make it difficult to draw conclusions about their effect on recruitment. A comprehensive approach that focuses on compensation, career advancement, improved working conditions and recognition of the value of direct care workers is likely needed.  Where possible, states should monitor the recruitment and retention approaches used and evaluate whether they have had the intended effect on the direct care workforce. Best practices identified by one state can inform other states’ resource allocation decisions.

The population continues to age. By 2035, more than 1 in 10 United States residents will be age 75 or older. The need to secure resources and identify strategies to allow individuals to receive care at home when desired while supporting the workforce that makes this possible is greater than ever.

Research for this piece was supported by Arnold Ventures.

The post Without supports for direct home care workers, older adults are at risk of unwanted nursing home admissions first appeared on The Incidental Economist.

How doctors can stop overlooking patients they’ve never seen

Today the Washington Post had a Q&A with a doctor about jerking while falling asleep (hypnic jerks). Because what is described resembles my condition (about which I posted yesterday), several people sent me the link. The quoted doctor may not understand how his words can cause harm, and how easy it would be for them not to.

The doctor addresses how hypnic jerks normally occur. In doing so, he misses how they, or things like them, can occur abnormally. Therefore, his advice comes off as insulting to those of us who struggle with sleep myoclonus and don’t have anxiety, aren’t stressed, and have already optimized sleep hygiene.

All he needed to add is, “If you have tried all this and still have problems, consult a specialist.” He could say more, if he knew more, but at least this would be enough to signal to patients like me that we’re heard. Without such words, we feel unwelcome by a health system that already has too little to offer us.

This is one big thing I’ve learned about having a rare disorder. Those with my condition, and undoubtedly others with rare disorders, are sometimes purposefully and sometimes accidentally dismissed. It’s frustrating and causes harm.

The post How doctors can stop overlooking patients they’ve never seen first appeared on The Incidental Economist.

The middle-age update post

I really had no intention of posting an update on some of the middle-age ailments I’ve written about before. But I keep getting questions about them, some by email. Because of ailment number one below, I just can’t respond at length to each email. So, here goes. You asked for this. (No, not all of you. If you didn’t, just stop reading.)

1. Arms: Backstory here. For work, and a little bit for non-work, I spend a lot of time with my hands on a keyboard, to say nothing of my face in a screen. Because I have to manage the tendinitis in my arms (see backstory), I can’t write as much email or other things as I used to or even want to. I just can’t. It hurts. This is also one reason why, more than I used to, I prefer to talk to people than to correspond back and forth by email. So, I’m not responding to your email unless I have to. It’s not you, it’s me.

2. Feet: Backstory here. It’s not plantar fasciitis. It was, as it turns out, never plantar fasciitis. But because I wrote a lot about plantar fasciitis, in part because every doc told me it was plantar fasciitis, people think I had/have plantar fasciitis. I do not have, and never have had, plantar fasciitis. (Yeah, I know I just wrote plantar fasciitis seven times in five sentences, including this one.)

Let’s do a little Q&A:

Q: So, what was/is it?

A: Nobody knows. It’s not important that we know what it is though.

Q: How do you know it was/is not plantar fasciitis?

A: See backstory. None of the data fit. None of the treatments for plantar fasciitis worked. Everything that worked was the opposite of plantar fasciitis advice. It’s not plantar fasciitis. Stop thinking it was.

Q: So what works?

A: Not wearing shoes, particularly not wearing structured shoes (with arch support), or shoes that get all snuggy around my heals. I’ve been barefoot about 98% of the time since the pandemic. When I wear something on my feet, it’s usually sandals or crocs. Even in New England winters, you can do almost anything in the right sandals and waterproof socks. Gradually, I’ve been able to tolerate shoes by Xero. After some years of this, and other things, I’m largely cured.

Q: What other things?

A: Massage (not just of my feet but of trigger points in my legs), toe stretches (look up “Yoga Toes”), and feet strengthening, but also rest.

Q: Whoa, that’s confusing. How do you strengthen and rest?

A: We do this all the time with other body parts. Nobody strengthens their biceps all the time, for example. You strengthen and you rest.

I rest when my feet hurt. I avoid things that make them hurt. Standing hurts more than walking. Walking on concrete hurts more than walking in the woods or on sand. I just do what feels better in every situation. I really work hard at avoiding a lot of standing. It’s awful. Stop standing around at parties for hours. Sit down a little!

But, also, when my feet can take it, I use them. I walk, preferably in ways that use the muscles hard (on sand, on hikes in the woods, not on concrete). I do balancing exercises that strengthen the feet, among other foot strengthening exercises. If you’re interested, look them up. I don’t need to explain them. I can’t tell you exactly what will work for you. If you need foot strengthening, do some trial and error to figure out what feels right to you and do some. Do less when they hurt.

Q: So, basically, you stopped listening to doctors and started listening to your body, right?

A: Yup. This wasn’t a quick cure, but I am largely cured. It’s management, just like my arms. No big deal now.

3. Sleep. Backstory here. (See also, this post.) For nearly three years, I’ve had a poorly understood, barely researched, super rare, sleep movement disorder — a sleep myoclonus. You almost certainly have not heard of it, don’t know what it is, and don’t have it. But if you think you do, the backstory post tells you how to find some support. If you want to study it, contact me. There are people desperate for studies, though fortunately not many (people that is — we’re desperate for as many (good) studies as you are willing to do).

It’s the most challenging thing I’ve ever had to deal with, and I will most likely be dealing with it for years to decades, if not the rest of my life.

I am now expert on sleep hygiene and sleep aids of all types. I have to be. With very high confidence I can say that there is no generic sleep advice out there that I have not seen. I have several specialists to help me, but they don’t know a lot about this either. Nobody does.

Most days are fine. I’ve had months of fine. But there are stretches that can last up to a few weeks that are really hard. It has changed me. Apart from the weeks when I’m very sleep deprived, I’m not necessarily “worse” than I was before I had this. I’m just different. My strengths and limitations are different. What I want to do is different. How I prefer to engage with people is different. My body’s temperature regulation is different. It’s all just different.

I’ve gotten really frustrated with this condition, really sad, really angry. But these feelings are not the norm and pass quickly. Just because it’s hard doesn’t mean I’m unhappy. I’m probably just as happy as anyone else.

I’ve learned a lot about myself and what exacerbates my condition. I cannot take on as much stress as I used to. Life and work has to be slower. I can do a lot, but just not as much. That’s fine. I was probably doing more than a normal amount before. I’m OK with normal.

After all, I am 50. Slowing down is fine. It’s good for my arms and feet too.

The post The middle-age update post first appeared on The Incidental Economist.

Free preventive care under the ACA is under threat again

Supreme Court case, Briarwood Management v. Becerra threatens access to preventative care under the ACA. TIE contributing author, Paul Shafer, describes the threat against preventative care in a piece in The Conversation.

The plaintiffs in Braidwood object to purchasing insurance that covers preexposure prophylaxis (PrEP). Texas Judge Reed O’Connor ruled that the requirement for insurance plans to cover PrEP violated the religious freedom of the plaintiffs.

PrEP is nearly 100% effective in preventing HIV infection. Its utilization has successfully reduced HIV diagnosis rates. If this Texas ruling were to extend nationally, it would impact 170,000 current PrEP users and over 1 million people who can benefit from using PrEP.

Read the full post here!

Research for this piece was supported by Arnold Ventures. 

The post Free preventive care under the ACA is under threat again first appeared on The Incidental Economist.